Business Description
TScan Therapeutics is a clinical-stage company based in Waltham, Massachusetts, focused on developing specialized immune cell treatments for cancer patients. Its leading therapy, TSC-101, is being tested in an early-stage clinical trial for patients with certain blood cancers who are undergoing stem cell transplants. The company is also working on a broader pipeline of treatments targeting both blood cancers and solid tumors, using engineered T cells designed to seek out and attack cancer cells. In addition, TScan has a research partnership with Amgen to study immune responses in patients with Crohn's disease.
